We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biopharmaceutical company CoTherix Inc. on Wednesday raised its full-year expense outlook, partly due to a licensing pact it signed with Japanese drug developer Asahi Kasei Pharma Corp.
The Switzerland-based Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets.
Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) announced today completion of common stock registration underlying the Series A Convertible Preferred stock and warrants sold in private placements in 2004 and 2005.
An Austrian court has ruled for drug firm Novogen in a patent dispute over the company's menopause symptom relief product Promensil, the Sydney, Australia-based drugmaker announced recently.
A recently published study shows multiple sclerosis (MS) drug Copaxone, marketed by Teva Pharmaceutical and sanofi-aventis, reduced annual relapse rates 75 percent in patients who switched to Copaxone from MS treatment Betaseron, the drugmakers said recently.
The FDA is facing increasing criticism from lawmakers about its enforcement policies, but it is unlikely to face true congressional pressure to strengthen those policies while Republicans maintain control of both the House and Senate, sources say.